,,ii  #aag? ,,congress  #b;d ,session   
,s4 #dcda  ,,9 ,,! ,,s5ate ,,( ,,!      
,,unit$ ,,/ates  ,may #bf1 #bjbb,ms4    
,ros5 7= h]self & ,mr4 ,romney7         
introduc$ ! foll[+ bill2 :i* 0 read     
twice & ref]r$ to ! ,committee on       
,heal?1 ,education1 ,labor1 & ,p5sions  
,a ,,bill  ,to require ! ,gov]nm5t      
,acc\ntability ,(fice to issue a report 
on nonpr(it ph>maceutical organizations4
  #a4 ,%ort title ,?is ,act may be cit$ 
z ! ,advanc+ ,af=dable ,m$ic9es =       
,families ,act4  #b4 ,,gao report on    
nonpr(it ph>maceutical organizations ,! 
,comptroll] ,g5]al ( ! ,unit$ ,/ates    
%all submit a report to ,congress on !  
foll[+3 7#a7 ,! pot5tial impact (       
nonpr(it ph>maceutical organizations on 
! availability & co/ ( drugs1 includ+ on
 drug %ortages1 consum] co/s1 & co/s to 
,f$]al programs4  7#b7 ,! pot5tial (    
nonpr(it ph>maceutical organizations to 
accel]ate developm5t ( new drugs1 g5]ic 
drugs1 new biological products1         
biosimil> biological products1 cell-bas$

 !rapies1 & devices4  7#c7 ,exi/+ b>ri]s
 to ! success ( nonpr(it ph>maceutical  
organizations1 includ+ ! ability ( su*  
organizations to obta9 tax-exempt /atus1
 access to capital1 & access to m>kets4 
7#d7 ,pot5tial actions by ,congress t   
w\ld all[ nonpr(it ph>maceutical        
organizations to deliv] b5efits to !    
ph>maceutical m>ket4